Geode Capital Management’s Verrica Pharmaceuticals VRCA Stock Holding History

Geode Capital Management’s Portfolio VRCA Stock Details VRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$846K	Sell	138,160 -757	-0.5%	-$4.72K	﹤0.01%	3420
2026 Q1	$735K	Buy	138,917 +71,258	+105%	+$456K	﹤0.01%	3455
2025 Q4	$562K	Hold	67,659	–	–	﹤0.01%	3547
2025 Q3	$292K	Buy	67,659 +3,043	+5%	+$18.4K	﹤0.01%	3806
2025 Q2	$343K	Sell	64,616 -37,233	-37%	-$200K	﹤0.01%	3675
2025 Q1	$450K	Buy	101,849 +54,122	+113%	+$350K	﹤0.01%	3581
2024 Q4	$334K	Buy	47,727 +2,179	+5%	+$23.9K	﹤0.01%	3727
2024 Q3	$661K	Sell	45,548 -788	-2%	-$35.5K	﹤0.01%	3499
2024 Q2	$3.38M	Buy	46,336 +1,405	+3%	+$108K	﹤0.01%	2930
2024 Q1	$2.66M	Buy	44,931 +1,963	+5%	+$108K	﹤0.01%	3005
2023 Q4	$3.15M	Buy	42,968 +1,289	+3%	+$53K	﹤0.01%	2927
2023 Q3	$1.62M	Buy	41,679 +2,828	+7%	+$144K	﹤0.01%	3145
2023 Q2	$2.24M	Buy	38,851 +20,763	+115%	+$1.26M	﹤0.01%	3075
2023 Q1	$1.18M	Buy	18,088 +1,792	+11%	+$108K	﹤0.01%	3270
2022 Q4	$448K	Buy	16,296 +1,272	+8%	+$33.9K	﹤0.01%	3707
2022 Q3	$438K	Buy	15,024 +2,910	+24%	+$99.7K	﹤0.01%	3787
2022 Q2	$232K	Sell	12,114 -9,626	-44%	-$484K	﹤0.01%	4173
2022 Q1	$1.76M	Sell	21,740 -43	-0.2%	-$3.54K	﹤0.01%	3313
2021 Q4	$2M	Sell	21,783 -2,024	-9%	-$229K	﹤0.01%	3358
2021 Q3	$2.98M	Buy	23,807 +2,509	+12%	+$281K	﹤0.01%	3185
2021 Q2	$2.41M	Buy	21,298 +1,382	+7%	+$167K	﹤0.01%	3209
2021 Q1	$3.02M	Buy	19,916 +1,439	+8%	+$199K	﹤0.01%	3049
2020 Q4	$2.13M	Sell	18,477 -155	-0.8%	-$14.2K	﹤0.01%	3051
2020 Q3	$1.44M	Sell	18,632 -1,120	-6%	-$91.7K	﹤0.01%	3056
2020 Q2	$2.17M	Buy	19,752 +1,745	+10%	+$202K	﹤0.01%	2793
2020 Q1	$1.97M	Buy	18,007 +1,683	+10%	+$221K	﹤0.01%	2682
2019 Q4	$2.59M	Buy	16,324 +1,951	+14%	+$288K	﹤0.01%	2847
2019 Q3	$2.12M	Buy	14,373 +6,181	+75%	+$689K	﹤0.01%	2910
2019 Q2	$951K	Buy	8,192 +2,034	+33%	+$191K	﹤0.01%	3255
2019 Q1	$665K	Buy	6,158 +2,467	+67%	+$285K	﹤0.01%	3317
2018 Q4	$300K	Buy	3,691 +889	+32%	+$108K	﹤0.01%	3557
2018 Q3	$455K	Buy	+2,802	New	+$479K	﹤0.01%	3496

Other funds holding VRCA

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Cannell Capital Alta, Wyoming $149M AUM 39.81% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Mariner Overland Park, Kansas $95.2B AUM 32.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Geode Capital Management's VRCA Position: Q2 2026 in Review

Geode Capital Management reduced its Verrica Pharmaceuticals (VRCA) stake by 0.54% in Q2 2026, selling an estimated $4.72K and leaving 138,160 shares worth $846K. The position accounts for ﹤0.01% of the portfolio, ranked #3420.

Geode Capital Management first reported a position in VRCA in Q3 2018 and has held it in 32 quarters since. The position peaked at $3.38M in Q2 2024. 43 funds tracked by Wall St. Rank hold VRCA as of Q2 2026.

Geode Capital Management held 138,160 shares of Verrica Pharmaceuticals worth $846K as of Q2 2026.
Geode Capital Management sold 757 Verrica Pharmaceuticals shares in Q2 2026, an estimated $4.72K.
Verrica Pharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3420 holding.
Geode Capital Management first reported a position in Verrica Pharmaceuticals in Q3 2018 and has held it in 32 quarters since.
Geode Capital Management's Verrica Pharmaceuticals position peaked at $3.38M in Q2 2024.
43 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.